The Fiscal Year 2016 (FY16) Defense Appropriations Act
provides $7.5 million (M) to the Department of Defense Epilepsy Research
Program (ERP). The ERP
supports research that will explore the causative links between TBI and
epilepsy, with the hope that one day post-traumatic epilepsy will be
preventable. As directed by the Office of the Assistant Secretary of
Defense for Health Affairs, the Defense Health Agency, Research, Development,
and Acquisition (DHA RDA) Directorate manages and executes the Defense Health
Program (DHP) Research, Development, Test, and Evaluation (RDT&E)
appropriation. The managing agent for the anticipated Program
Announcements/Funding Opportunities is the Congressionally Directed Medical
Research Programs (CDMRP).
The ERP is providing the information in this pre-announcement to allow investigators time to plan and develop applications. The FY16 ERP Program Announcement and General Application Instructions for the following award mechanism are anticipated to be posted on the Grants.gov website in July 2016. Pre-application and application deadlines will be available when the Program Announcements are released. This pre-announcement should not be construed as an obligation by the government.
The ERP is providing the information in this pre-announcement to allow investigators time to plan and develop applications. The FY16 ERP Program Announcement and General Application Instructions for the following award mechanism are anticipated to be posted on the Grants.gov website in July 2016. Pre-application and application deadlines will be available when the Program Announcements are released. This pre-announcement should not be construed as an obligation by the government.
FY16 ERP
Focus Areas:
All applications for the FY16 ERP funding opportunities must
address at least one of the following FY16 Focus Areas. An application
that proposes research outside of these FY16 Focus Areas is acceptable, as long
as the applicant provides a strong rationale as to the relevance of the
research to the ERP’s mission.
The ERP FY16 Focus
Areas are as follows:
Epidemiology: Epidemiological characterization of post
traumatic epilepsy (PTE) following TBI, which may include:
· Risk
factors such as demographics, genetic factors, organic head injury factors, or
type of insult
· Differentiation
of PTE and Psychogenic Non-Epileptic Seizures (PNES)
· Outcomes
including latency to epilepsy, morbidities and comorbidities, and mortality
· Pre-existing
conditions including psychological and psychiatric risk factors
Markers and
Mechanisms: Identifying
markers or mechanisms (via clinical or preclinical models) that address PTE:
· Early
detection
· Diagnosis
· Prognosis
· Comorbidity
· Mortality
· Risk
stratification
Models of
PTE: Development of new models or better
characterization of existing etiologically relevant models for PTE, including
repetitive TBI.
Psychogenic
Non-Epileptic Seizures:
Exploration of the epidemiology, mechanisms, risk factors, or markers of PNES
subsequent to TBI. Research on non-pharmacological interventions in this
population is also encouraged.
The FY16 ERP will offer
the Idea Development Award. This Award Mechanism will offer two levels of
research funding.
Idea
Development Award
For either Level I or
II, the PI must be an independent investigator at or above the level of
Assistant Professor (or equivalent).
Intent: Solicit research to understand the magnitude
and underlying mechanisms of Post Traumatic Epilepsy (PTE), especially in
Service members and Veterans while benefitting the civilian community.
Level
I: Intended to support
investigator-initiated research that may be high-risk and/or high-gain.
Level
II: Intended to support
advanced studies that may be multidisciplinary in nature, and/or have multiple
collaborators.
Applications should
provide relevant preliminary data to support the application’s research
hypothesis (or hypotheses).
Preproposal
submission is required; application submission is by invitation only.
Level I:
· Funding limit is
$500,000 direct costs.
· Maximum period of
performance is 3 years.
· Indirect costs
may be proposed in accordance with the institution's rate agreement.
Level II:
· Funding limit is
$3.7M total (direct and indirect) costs.
Maximum period of
performance is 4 years.
A pre-application is
required and must be submitted through the electronic Biomedical Research
Application Portal (eBRAP) at https://eBRAP.org prior
to the pre-application deadline. All applications must conform to the
final Program Announcements and General Application Instructions that will be
available for electronic downloading from the Grants.gov website. The application package
containing the required forms for each award mechanism will also be found on Grants.gov. A listing of all CDMRP
funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA
Number 12.420.
Applications must be submitted through the federal government's
single-entry portal, Grants.gov.
Submission deadlines are not available until the Program Announcements are
released. For email notification when Program Announcements are released,
go to the CDMRP website (http://cdmrp.army.mil)
and select Subscribe to Funding Opportunities & Program
Communications. For more information about the ERP or other
CDMRP-administered programs, please visit the CDMRP website (http://cdmrp.army.mil).
For questions about the
research programs, please contact the MRO Research Grants & Contracts Team
(adm-researchgrants.contracts@monash.edu).
No comments:
Post a Comment